Immunotherapeutic Strategies in RRMM: Differentiating Between Emerging Approaches
Release Date: March 05, 2020
Expiration Date: March 05, 2021
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
In support of the community oncology practitioner, this activity provides the most up-to-date advances and strategies for treating relapsed/refractory myeloma while supporting the translation of this information into practice through provision of applied clinical tools and resources.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, pharmacists and other allied healthcare professionals who provide care to patients with smoldering or and newly diagnosed multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Compare CAR T-cell therapies and other emerging immunotherapeutic strategies in MM, differentiating between the mechanisms of action and disease and patient types currently being investigated for each
- Summarize recent results of ongoing clinical trials of emerging immunotherapies for RRMM
- Outline patient- and disease-related characteristics that would indicate a RRMM patient would be suitable for participation in a clinical trial of an emerging immunotherapy
Immunotherapeutic Strategies in RRMM: Differentiating Between Emerging Approaches – Irene Ghobrial, MD
Instructions for Participation and Credit
This activity is eligible for credit through March 05, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Harvard Medical School
Dr. Irene Ghobrial received her medical degree from Cairo University School of Medicine, Egypt. She completed her internal medicine training at Wayne State University, and her hematology/oncology subspecialty training at Mayo Clinic College of Medicine. She is currently a Professor at Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, and an Associate Member of the Broad Institute, Cambridge. Dr. Ghobrial is also Director of the Clinical Investigator Research Program at DFCI, Co-director of the Center for Prevention of Progression (CPOP), and Co-leader of the Blood Cancer Research Partnership (BCRP). In addition, she is the Director of the Michele & Stephen Kirsch Laboratory.
Dr. Ghobrial’s research focuses on understanding mechanisms of tumor progression from early precursor conditions, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering disease to symptomatic multiple myeloma (MM) and Waldenström macroglobulinemia (WM). She specifically focuses on the role of the malignant bone marrow niche in regulating disease progression. Dr. Ghobrial is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages before clonal evolution occurs. She has authored/co-authored over 250 publications and book chapters and has received funding support from the National Cancer Institute (NCI) as well as multiple foundations including Stand Up to Cancer, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, and the International Myeloma Foundation. She has received multiple awards including the Ken Anderson Young Investigator Award, Robert A. Kyle Award for Research in Waldenström Macroglobulinemia, and Mentor of the Year Award at DFCI.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-012-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Irene Ghobrial has received honoraria related to formal advisory activities from GlaxoSmithKline plc, AbbVie Inc., and Bristol-Myers Squibb Company, as well as consultant fees from AbbVie, Adaptive Biotechnologies, Aptitude Medical Systems, Bristol-Myers Squibb, Celgene Corporation, Cellectar Biosciences, Inc., Curio Biotech Ltd., Genentech, Inc., GlaxoSmithKline, GNS Healthcare, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Medscape, Oncopeptides, AB, Sanofi, and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Jami Craig, Project Manager, Wilma Guerra, Program Director, Andrew D. Bowser, ELS, CHCP, medical writers, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.